-+ 0.00%
-+ 0.00%
-+ 0.00%

VISTAGEN THERAPEUTICS - ESTIMATES SEVERANCE AND TERMINATION COSTS OF ABOUT $1 MLN - SEC FILING

Reuters·10/30/2026 21:25:02

Please log in to view news